Clinical trials: Epithelial Neoplasms, Malignant
Esophageal Cancer, Chemoradiotherapy
Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
Definitive chemoradiotherapy (CRT) is the standard treatment for locally advanced unresectable esophageal cancer, but its efficacy remains unsatisfactory.
- Trial name
- EC-CRT-008 (NCT07177794)
- Testing
- toripalimab, capecitabine
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Sun Yat-sen University
Endometrial Hyperplasia, Endometrial Cancer
Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer
This study, conducted jointly by the National Cancer Institute and the Kaiser Permanente Center for Health Research Northwest (KPCHRN) in Portland, Oregon, will lay the groundwork for a future study to identify precursors of…
- Conditions
- Endometrial Hyperplasia, Endometrial Cancer, Postmenopausal Bleeding, Vaginal Bleeding
- Trial name
- NCT00339651
- Where
- United States
- Volunteers
- 745 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
- Trial name
- NCT05544929
- Testing
- KFA115, pembrolizumab
- Where
- 18 sites in United States, Canada and 10 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with surgery may kill more tumor cells.
- Trial name
- NCT00003231
- Testing
- cisplatin, docetaxel, surgical procedure
- Where
- 9 sites in Switzerland
- Volunteers
- 40 people
- Sponsor
- Swiss Cancer Institute
Neoplasms, Non-small-cell Lung Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
The purpose of this study is to learn about the: safety (the effect of the study medicine on the participant's body), effects of the study medicine alone or in combination with sasanlimab - the best amount of the study medicine.
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
- Trial name
- NCT06546553
- Testing
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Non-Muscle Invasive Bladder Cancer
Machine Learning-Based Prediction of BCG Response in High-Risk Non-Muscle Invasive Bladder Cancer Patients
This prospective study aims at using Artificial intelligence to create a helpful unbiased machine learning-based model that predicts BCG unresponsiveness in high risk BCG-naïve NMIBC patients incorporating all potential…
- Trial name
- NCT05332353
- Testing
- Bacillus Calmette-Guerin
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Relapsed Epithelial Ovarian Cancer, Relapsed Primary Peritoneal Cancer
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
This is a dose escalation study in female subjects with relapsed ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer).
- Conditions
- Relapsed Epithelial Ovarian Cancer, Relapsed Primary Peritoneal Cancer, Relapsed Fallopian Tube Cancer
- Trial name
- NCT01940172
- Testing
- Birinapant, Conatumumab
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- TetraLogic Pharmaceuticals
Head and Neck Neoplasms, Hearing Disorder
Hearing Loss and the Effects of Statin Drugs in People With Head and Neck Squamous Cell Carcinoma Treated With Cisplatin Chemoradiation
Background: Cisplatin is a chemotherapy drug. It is used to treat head and neck squamous cell carcinoma (HNSCC) and other cancers. It can cause hearing loss for some people.
- Conditions
- Head and Neck Neoplasms, Hearing Disorder, Hyperlipidemia
- Trial name
- NCT03225157
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Stage I Oral Cavity Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma
Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer
This randomized phase II clinical trial studies how well photodynamic therapy with HPPH works compared to standard of care surgery in treating patients with oral cavity cancer.
- Trial name
- NCT03090412
- Testing
- HPPH, Laboratory Biomarker Analysis, Photodynamic Therapy
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Roswell Park Cancer Institute
Oligodendroglioma, Low-grade Oligodendroglioma
A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery
Because of their prolonged survival, patients with 1p/19q-codeleted low-grade oligodendrogliomas treated with RT + PCV are at risk of neurocognitive deterioration.
- Conditions
- Oligodendroglioma, Low-grade Oligodendroglioma, 1p19q Codeletion
- Trial name
- POLO (NCT04702581)
- Testing
- PCV chemotherapy, Radiotherapy and PCV chemotherapy
- Where
- 26 sites in France
- Volunteers
- 280 people
- Sponsor
- Hospices Civils de Lyon
Small-cell Lung Cancer
Watchful Observation of Patients With LD-SCLC Instead of the PCI
Prophylactic cranial irradiation (PCI) is a current standard of care after confirmed response to radical chemoradiotherapy for limited disease small cell lung cancer (LD-SCLC).
- Trial name
- PCILESS (NCT04168281)
- Testing
- Magnetic resonance imaging (MRI)
- Where
- Poland
- Volunteers
- 80 people
- Sponsor
- Sergiusz Nawrocki
Breast Cancer
Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00072319
- Testing
- filgrastim, cyclophosphamide, epirubicin hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Oropharyngeal Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
This is a phase II clinical trial. The purpose of this study is to determine the feasibility of deescalating chemoradiation treatment based on mid-treatment tumor response determined by rapid nodal shrinkage and clearance of…
- Trial name
- NCT03215719
- Testing
- Standard Radiation Treatment, Dose-Deescalated Treatment, Cisplatinum
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- NYU Langone Health
Head and Neck Carcinoma
Effects of Human Papillomavirus Diagnosis on Relationships of Patients With Head and Neck Cancer
This trial studies the effects of human papillomavirus diagnosis on the relationships of patients with head and neck cancer. Determining the effects of human papillomavirus diagnosis on relationships may determine whether human…
- Trial name
- NCT04666428
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Thomas Jefferson University
Lung Cancer Non-Small Cell Cancer (NSCLC)
Cross-sectorial Rehabilitation of Patients with Lung Cancer
Four thousand seven hundred patients are diagnosed with lung cancer in Denmark every year. Even though cigarette smoking has declined for decades a decline in lung cancer incidence is still at least a decade away.
- Trial name
- NCT06705465
- Testing
- video conference
- Where
- Denmark
- Volunteers
- 130 people
- Sponsor
- Camilla Balle
HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma
Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs
This research study is testing whether a new study drug (called ATRN-119) is safe and effective when combined with a single, highly targeted dose of radiation therapy (called stereotactic body radiation therapy or SBRT) to treat…
- Conditions
- HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma, HPV Associated Cancers
- Trial name
- NCT07578467
- Testing
- ATRN-119, Stereotactic Body Radiation Therapy (SBRT)
- Volunteers
- 35 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Esophageal Cancer, Recurrence
Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
The prognosis of patients with esophageal squamous cell carcinoma (ESCC) who develop post-operative early tumor recurrence is often relatively poor.
- Conditions
- Esophageal Cancer, Recurrence, DNA Methylation
- Trial name
- NCT06476067
- Testing
- Surgery
- Where
- 2 sites in Japan
- Volunteers
- 150 people
- Sponsor
- City of Hope Medical Center
Head and Neck Cancer
Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI
The goal of this clinical research study is to learn if ferumoxytol, when given at the time of a magnetic resonance imaging (MRI), can help researchers learn more about the spread of certain kinds of cancers.
- Trial name
- NCT01895829
- Testing
- Magnetic Resonance Imaging (MRI), Ferumoxytol
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Diarrhea, Drug/Agent Toxicity by Tissue/Organ
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma
- Trial name
- NCT00093353
- Testing
- cefixime, irinotecan hydrochloride, temozolomide
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Squamous Cell Carcinoma of the Head and Neck
Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.
A single-arm, single-center clinical trial evaluating efficacy (Phase #)
- Trial name
- NCT07550972
- Testing
- A single-arm, single-center clinical trial evaluating efficacy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Provincial People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.